Related Experiment Video
Updated: Oct 19, 2025
07:04
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.5K
CFTR modulator use in post lung transplant recipients.
Lauryn A Benninger1, Cesar Trillo1, Jorge Lascano1
1Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida College of Medicine, Gainesville, Florida.
Summary
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy, like Trikafta, shows promise in lung transplant recipients. This therapy may improve cystic fibrosis symptoms without negatively affecting lung transplant graft function or immunosuppression.
Area of Science:
- Pulmonology
- Transplant Surgery
- Pharmacology
Background:
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy was previously contraindicated in solid organ transplant recipients due to limited data and concerns about drug interactions.
- Potential benefits of CFTR modulators in improving extrapulmonary manifestations of cystic fibrosis in lung transplant recipients were unexplored.
Purpose of the Study:
- To evaluate the safety and efficacy of elexacaftor/tezacaftor/ivacaftor (Trikafta) in adult post-lung transplant recipients.
- To assess the impact of CFTR modulator therapy on graft function and immunosuppressive drug levels in this patient population.
Main Methods:
- Single-center retrospective study.
- Inclusion of adult patients who received lung transplants and were subsequently treated with elexacaftor/tezacaftor/ivacaftor.
- Monitoring of pulmonary function, extrapulmonary manifestations, graft function, and immunosuppressive drug levels.
Main Results:
- Elexacaftor/tezacaftor/ivacaftor treatment in post-lung transplant recipients was associated with improvements in extrapulmonary manifestations of cystic fibrosis.
- No significant negative impact on lung transplant graft function was observed.
- Immunosuppressive drug levels remained stable during CFTR modulator therapy.
Conclusions:
- CFTR modulator therapy, specifically elexacaftor/tezacaftor/ivacaftor, appears to be a viable option for managing cystic fibrosis in adult post-lung transplant recipients.
- This therapy may offer benefits for extrapulmonary symptoms without compromising graft integrity or immunosuppressive efficacy.
Keywords:
CFTRCFTR modulatorcalcineurin inhibitorscystic fibrosisimmunosuppressionlung transplantationMore Related Videos
Related Concept Videos
01:24Cystic Fibrosis: Management
254
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
254
01:26COPD: Management Using Bronchodilators and Corticosteroids
478
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
478
01:23Cystic Fibrosis: Pathogenesis
426
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
426
01:19Antiasthma Drugs: Leukotriene Modifiers
688
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
688
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:17Drugs Used in Lower Respiratory Disorders: Overview
712
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
712